Predictive factors for response and progression after treatment with rituximab in previously untreated patients with Waldenstrom's macroglobulinemia (WM).

被引：0
|
作者：
Anagnostopoulos, A
Treon, SP
Zervas, K
Branagan, A
Gika, D
Zomas, A
Kyrtsonis, MC
Vassou, A
Anagnostopoulos, N
Pangalis, G
Dimopoulos, MA
机构：
[1] Greek Myeloma Study Grp, Dept Clin Therapeut, Athens, Greece
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3485
引用
收藏
页码：973A / 973A
页数：1
相关论文
共 50 条
  • [31] Association of maintenance rituximab with clinical outcome in rituximab-naive patients with Waldenstrom's macroglobulinemia (WM) who respond to a rituximab containing regimen
    Ioakimidis, L. I.
    Hanzis, C. A.
    Manning, R. J.
    Patterson, C. J.
    Soumerai, J. D.
    Hunter, Z. R.
    Brodsky, P. S.
    Sheehy, P. S.
    Turnbull, B.
    Treon, S. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM.
    Chen, C. I.
    Kouroukis, T.
    White, D.
    Voralia, M.
    Stadtmauer, E.
    Wright, J.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 432S - 432S
  • [33] Prospective evaluation of rituximab for the treatment of Waldenstrom's macroglobulinemia.
    Dimopoulos, MA
    Kiamouris, C
    Karkantaris, C
    Mitsouli, C
    Viniou, N
    BLOOD, 2000, 96 (11) : 169A - 169A
  • [34] Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial
    Buske, C.
    Tedeschi, A.
    Trotman, J.
    Garcia-Sanz, R.
    MacDonald, D.
    Leblond, V
    Mahe, B.
    Herbaux, C.
    Tam, C. S.
    Palomba, M. L.
    Matous, J., V
    Shustik, C.
    Kastritis, E.
    Treon, S. P.
    Li, J.
    Salman, Z.
    Graef, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 252 - 252
  • [35] Rituximab alone or in combination in the frontline treatment of Waldenstrom's macroglobulinemia
    Weber, D. M.
    Thomas, S.
    Wang, M.
    Alexanian, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 87 - 88
  • [36] Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia
    Kanan, Sandra
    Meid, Kirsten
    Treon, Steven P.
    Castillo, Jorge J.
    BLOOD, 2014, 124 (21)
  • [37] Efficacy and safety of cladribine (2CDA) and Rituximab® combination treatment for patients with Waldenstrom's Macroglobulinemia (WM):: Reports of a multicenter study
    Laszlo, D.
    Sammassimo, S.
    Andreola, G.
    Rabascio, C.
    Cascio, R.
    Pinto, A.
    Fabbri, A.
    Rigacci, L.
    Martinelli, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 238 - 238
  • [38] Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Xie, Wanling
    Padmanabhan, Swaminathan
    Badros, Ashraf
    Rourke, Meghan
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Poon, Tiffany
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul G.
    Treon, Steven P.
    Weller, Die
    Matous, Jeffrey
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (09) : 670 - 674
  • [39] Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia Treated with Ibrutinib
    Castillo, Jorge J.
    Gustine, Joshua
    Demos, Maria
    Keezer, Andrew
    Meid, Kirsten
    Chan, Gloria G.
    Chen, Jiaji G.
    Guerrera, Maria Luisa
    Kofides, Amanda
    Munshi, Manit
    Tsakmaklis, Nicholas
    BLOOD, 2019, 134
  • [40] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia
    Dimopoulos, MA
    Hamilos, G
    Zervas, K
    Symeonidis, A
    Kouvatseas, G
    Roussou, P
    Gika, D
    Karmiris, T
    Bourantas, K
    Zomas, A
    Mitsouli, C
    Xilouri, I
    Vervessou, E
    Matsis, K
    Anagnostopoulos, N
    Economopoulos, T
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1299 - 1305
12345